ADVISOR CONNECT | OUR TEAM
This page is currently being updated.
TOOLS & DOWNLOADS
Specialty Pharmacy Management Report
>> Download The Full Report
On June 28, 2016, FDA approved Gilead’s new drug, Epclusa, to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients with moderate to severe cirrhosis (decompensated cirrhosis), Epclusa is approved for use in combination with the drug ribavirin.read more
EMPLOYEE BENEFIT NEWS